Akero Therapeutics, Inc. AKRO
We take great care to ensure that the data presented and summarized in this overview for Akero Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKRO
View all-
Janus Henderson Group PLC London, X06.28MShares$340 Million0.14% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$311 Million9.63% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million3.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$245 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.25MShares$230 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$217 Million5.99% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.96MShares$214 Million2.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.81MShares$206 Million0.02% of portfolio
-
State Street Corp Boston, MA3.41MShares$185 Million0.01% of portfolio
Latest Institutional Activity in AKRO
Top Purchases
Top Sells
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at AKRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2025
|
Jonathan Young Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
9,259
-4.42%
|
-
|
|
Nov 25
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
152,678
+8.85%
|
$1,984,814
$13.02 P/Share
|
|
Nov 24
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,550
+2.0%
|
$288,650
$23.51 P/Share
|
|
Nov 20
2025
|
Andrew Cheng President and CEO |
SELL
Bona fide gift
|
Direct |
74,538
-14.58%
|
-
|
|
Nov 17
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
37,100
-22.27%
|
-
|
|
Nov 12
2025
|
Andrew Cheng President and CEO |
SELL
Bona fide gift
|
Direct |
14,739
-2.8%
|
-
|
|
Nov 04
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,266
+5.38%
|
$198,384
$24.73 P/Share
|
|
Oct 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.39%
|
$1,590,000
$53.98 P/Share
|
|
Oct 10
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.12%
|
$570,000
$19.87 P/Share
|
|
Oct 08
2025
|
G. Walmsley Graham |
BUY
Exercise of conversion of derivative security
|
Direct |
90,832
+25.76%
|
$1,816,640
$20.53 P/Share
|
|
Oct 08
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
52,212
+9.03%
|
$0
$0.62 P/Share
|
|
Oct 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.51%
|
$575,000
$46.41 P/Share
|
|
Oct 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.53%
|
$350,000
$28.35 P/Share
|
|
Oct 01
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.03%
|
$587,500
$47.81 P/Share
|
|
Oct 01
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.63%
|
$262,500
$21.1 P/Share
|
|
Sep 11
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,796
-0.38%
|
$77,228
$43.02 P/Share
|
|
Sep 11
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
553
-0.33%
|
$23,779
$43.02 P/Share
|
|
Sep 11
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
659
-1.13%
|
$28,337
$43.02 P/Share
|
|
Sep 11
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
659
-0.72%
|
$28,337
$43.02 P/Share
|
|
Sep 11
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
586
-0.3%
|
$25,198
$43.02 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 304K shares |
|---|---|
| Exercise of conversion of derivative security | 873K shares |
| Open market or private purchase | 400K shares |
| Bona fide gift | 164K shares |
|---|---|
| Open market or private sale | 851K shares |